Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Paradigm Biocapital Advisor purchased 750,000 shares of Olema Pharmaceuticals in Q4 2025, increasing the quarter-end position value by $122.09 million. The transaction signals institutional accumulation in the biotech name and could exert modest upward pressure on Olema's shares in the near term.

Analysis

Paradigm Biocapital Advisor purchased 750,000 shares of Olema Pharmaceuticals in Q4 2025, increasing the quarter-end position value by $122.09 million. The transaction signals institutional accumulation in the biotech name and could exert modest upward pressure on Olema's shares in the near term.